Coronary diseaseDay 2

SOLACI-SOCIME 2022 | Treatment Consideration in Women: Results from the RECOVER III Study – By Dr. Alexandra Lansky

solaci
solaci
590
0

Disfrute esta conferencia magistral brindada por la Dra. Alexandra Lansky durante el Congreso SOLACI-SOCIME 2022 realizado en Expo Santa Fé, CDMX los días 4, 5 y 6 de agosto de 2022.

Tema: Treatment Consideration in Women: Results from the RECOVER III Study

Suscríbase a nuestro newsletter semanal

Reciba resúmenes con los últimos artículos científicos

Previous article
The Best Moments of SOLACI-SOCIME 2022
Next article
SOLACI-SOCIME 2022 | The future of the innovation in cardiovascular interventions – Dr. Chaim Lotan
solaci
solaci

More articles by this author

Drugs for the Treatment of No-Reflow During PCI

Dr. Omar Tupayachi - 0
The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Dr. Omar Tupayachi - 0
Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

Dr. Omar Tupayachi - 0
In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

Dr. Omar Tupayachi - 0
The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Acute coronary syndromes

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in...
Dr. Omar Tupayachi -
SOLACI Sessionsspot_img

Recent Articles

Drugs for the Treatment of No-Reflow During PCI

Dr. Omar Tupayachi - 0
The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Coronary revascularization before TAVI: prior PCI or conservative management?

Dr. Juan Manuel Pérez - 0
The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Dr. Omar Tupayachi - 0
Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...